


# Unlocking the Biological Impact of Developmental Cannabis and Its Psychiatric Risk



**Yasmin Hurd**  
Director, Addiction Institute of Mount Sinai  
Chair of Translational Neuroscience  
Icahn School of Medicine at Mount Sinai  
Depts Psychiatry, Neuroscience and  
Pharmacological Sciences

# Cannabis

## Recreational



- No harm
- “healthy”, “organic” plant
- Not addictive
- Anxiolytic
- “Wonder drug”: can treat numerous conditions/disorders

## Medicinal



- Psychopathology
  - Psychosis/schizophrenia
  - Negative affective disorders
- Anxiogenic
- Addiction risk



Cannabis contains over 500 chemicals including  
>140 cannabinoids which have a greater or  
lesser degree of psycho-pharmaco-activity

Complex plant



# CANNABIS TODAY

Cannabis contains over 500 chemicals including >140 cannabinoids which have a greater or lesser degree of psycho-pharmaco-activity

Historic concentrated, high potency Products; varied routes of administration

Hemp/CBD  $\xrightarrow{\text{Chemical synthetic conversion}}$   $\Delta^8$ -THC other THC analogs (e.g.,  $\Delta^9$ -THC and hexahydrocannabinol [HHC] )


Tetrahydrocannabiphorol (THC-P) – rare cannabinoid (now synthetically made); extremely potent (>30%)  $\Delta^9$ -THC

The collage includes a line graph showing the increase in THC and CBD percentages in cannabis from 1995 to 2022. The THC percentage (blue line) has risen from approximately 4% to over 15%, while the CBD percentage (green line) has risen from approximately 0.3% to over 0.8%. A cloud of cannabinoid names (THC, CBD, CBG, CBN, etc.) is shown, along with a hexagonal diagram of terpenes. At the bottom, there is a collection of various cannabis products, including oils, edibles, and concentrates.


Year	THC %	CBD %
1995	4.0	0.37
1996	4.1	0.41
1997	4.1	0.41
1998	4.2	0.42
1999	4.5	0.45
2000	4.7	0.47
2001	4.7	0.47
2002	4.9	0.49
2003	5.1	0.51
2004	5.5	0.55
2005	6.0	0.60
2006	6.5	0.65
2007	7.0	0.70
2008	7.5	0.75
2009	8.0	0.80
2010	8.5	0.85
2011	9.0	0.90
2012	9.5	0.95
2013	10.0	1.00
2014	10.5	1.05
2015	11.0	1.10
2016	11.5	1.15
2017	12.0	1.20
2018	12.5	1.25
2019	13.0	1.30
2020	13.5	1.35
2021	14.0	1.40
2022	15.61	1.561

# Cannabis contains over 500 chemicals including >140 cannabinoids which have a greater or lesser degree of psycho-pharmaco-activity

# Historic **concentrated**, high **potency** Products; varied **routes** of administration


Hemp/CBD  **Chemical synthetic conversion** **Δ<sup>8</sup>-THC** other THC analogs (e.g., **Δ<sup>10</sup>-THC** and hexahydrocannabinol [**HHC**] )

Tetrahydrocannabiphorol (**THC-P**) – rare cannabinoid (**now synthetically made**); extremely potent (>30%)  $\Delta^9$ -THC






# Cannabis use increasing



Growth in cannabis prevalence and frequency of use reported in NSDUH since 1979 (indexed: level = 100 in 1992). NOTES: NSDUH = National Survey on Drug Use and Health; PM = past month. SOURCE: Caulkins, 2024.

# People using cannabis daily/near daily now exceeds alcohol



NOTES: Data presented are based on the NSDUH, which underwent methodological changes in 2020 and 2021. NSDUH = National Survey on Drug Use and Health.  
SOURCE: Reproduced from Caulkins, 2024.



A close-up photograph of several green, serrated leaves, likely from a plant like cannabis, against a dark green background. The leaves are arranged in a fan-like pattern, with their serrated edges clearly visible. The lighting is soft, highlighting the texture of the leaf surfaces.


**Complex plant**

**Complex endogenous biology**  
**Complex mechanisms of action**

# Endocannabinoid System



$\Delta^9$ -THC




Plant-derived cannabinoids

## Relatively Recent Discovery

N-arachidonylethanolamine (anandamide) (AEA) — 1992

2-arachidonoylglycerol (2-AG) — 1995

Endogenous cannabinoids = endocannabinoids



**AEA, anandamide; 2-AG, 2-arachidonoylglycerol**

- Synthesized on demand
- Synthesized from lipid (fatty acid) precursors

Cannabinoid receptors: CB1, CB2




# Endocannabinoid System

Endogenous cannabinoids = endocannabinoids



$\Delta^9$ -THC



Plant-derived cannabinoids

- AEA, anandamide;**  
**2-AG, 2-arachidonoylglycerol**
- Synthesized on demand
  - Synthesized from lipid (fatty acid) precursors

Cannabinoid receptors: CB1, CB2

# Endocannabinoid System

## Key Modulator

CB1  
CB2  
GPR55  
GPR35  
GPR19  
GPR18  
TRPV1, 2  
TRPV8  
PPAR


AEA  
2AG  
FAAH  
MAGL  
PLC  
DAGL

- Energy metabolism
- Appetite
- Thermoregulation
- Immune function and inflammation
- Neural development
- Learning and memory
- Pain and nociception
- Psychomotor function
- Sleep/wake cycle
- Stress and emotion regulation
- Reproduction


Cannabinoid receptors: CB1, CB2



# Endocannabinoid System




**Widely abundant neuromodulatory system:  
Finetunes synaptic transmission regulating  
communication between cells**






# Cannabis and Psychiatric Risk

## High psychiatric comorbidity



- Cannabis use disorder
- Schizophrenia
- Cannabis-induced psychosis
- Psychotic and nonpsychotic unipolar depression and bipolar disorder
- Anxiety
- Depression

*Estimated past-year diagnosis of cannabis use disorder amongst cannabis users is approximately 30%*







# Endocannabinoid System – Critical Role in Neurodevelopmental Processes

Fetal

Infancy

Childhood

Adolescence

Young adults

Neurogenesis

Migration

Synaptogenesis

Programmed cell death

brain

Fine tuning of neural circuits

Maturation of prefrontal cortex

Synaptic pruning

myelination



15.1% indoor cannabis smoking

Past year cannabis use by teens:  
8<sup>th</sup> graders: 11.4%  
9<sup>th</sup> graders: 28%  
12<sup>th</sup> graders: 35%



# The Endocannabinoid System and Neurodevelopment

## CB<sub>1</sub>R mRNA Expression in the Human Fetal Brain










# Molecular Dysregulation in the Human Fetal Brain Associated with *In Utero* Cannabis Exposure

## Cytoskeletal

### Proenkephalin: opioid neuropeptide



DiNieri et al et al. Biol Psychiatry, 2012


**Cytoskeleton:** a structure that helps cells maintain their shape and internal

**Opioid neuropeptides (enkephalin):** play a


**Dopamine:** mediates reward, goal-mediated behavior, learning, attention, memory, motor function ...

► Specificity of the neurobiological findings to cannabis exposure

Dopamine D2 Gene




Long-term consequences of adult brain and behavior?



DiNieri et al., *Biological Psychiatry*, 2012


PND2 (≈ f

Impaired LTD induction




(≈ young adult)

Tortoriello et al., *EMBO J*, 2014







# Stress (and Cannabis) in Pregnancy Project



Yoko Nomura

Hurricane Superstorm Sandy - 2012

## Pregnancy

Pre-Sandy

During-Sandy

Post-Sandy

### Delivery

- Cord blood
- Placenta biopsies
- Meconium

### Follow-up of child from 6 months

- Physical development
- Neurobehavioral assessment/emotional/social development
- Semi-structured clinical interviews (e.g., Preschool Age Psychopathological assessment)
- Psychophysiological measures
- Maternal psychological state
- Maternal substance use
- Environmental exposure
- Biospecimens (hair, nails)




# Placenta – The “Third Brain”


-Link between the fetal and maternal brains

## Does Cannabis Impact Placental Environment?

### RNA-sequencing




### Placenta support fetal neurodevelopment





**Placental programming is essential for neurodevelopment and aberration linked to psychiatric risk**



# Dysregulation of Immune Gene Expression in Placenta With Maternal Cannabis Use





*CNR1 = cannabinoid receptor type 1*



Includes several proinflammatory cytokine/chemokines (*IL1B*, *CXCL8*, *CCL2*) and enrichment for key immune function ontology such as type I interferon pathway, cytokine-mediated signaling, and neutrophil migration,



# Differentially Expressed Genes in the Placenta Associated with Cannabis Use



● upregulated DEGs. ● Downregulate DEGs. ● Immune DEGs




Anissa Bara




Teesta Naskar

# Human Placenta — Sex Differences with Cannabis Exposure



## Ontology Enrichment for Human Male Placenta



**Immune-related DEGs**



# Translational Animal Model: Cannabinoid Exposure To Pregnant Dams




Anissa Bara






Teesta Naskar

## Immune Transcriptome Dysregulation

Males




Females





Translational vapor rat model of prenatal cannabis (THC + CBD; 10:1) exposure

# Translational Animal Model: THC Exposure To Pregnant Dams Alters the Placental Immune Proteome

Human




Rat






# IDO1



- ❖ Catalyzes the degradation of **L-Tryptophan**, the precursor of **Serotonin** and downstream to **Melatonin**
- ❖ Rate-limiting step of catabolism along the **Kynurenine** pathway
- ❖ Crucial for **survival**
- ❖ Produced by cells in responses of **inflammation**
- ❖ Crucial for **Immune** Suppression and Autoimmunity (**protects the fetus from maternal immune rejection**)
- ❖ **Role in placental vascular development** (formation of new placental vessels!)

# Prenatal Cannabinoid Exposure Decreases Placental Serotonin Levels in Males

## Serotonin









Yoko Nomura

# Prenatal Environment Influences Future Phenotype?




# Maternal Cannabis Use in Relation to Hair Steroid Hormones And Clinical Behavior Scores in Early Childhood

## Significant Clinical Behavioral Scores at age 4



## Steroid hormone: 3-4 years old



Behavioral assessment system for children (BASC-2) survey


Rompala et al., PNAS 2021




# Prenatal Cannabis Exposure and Stress

## Synergistic Interaction



Risk (adjusted odds ratio) of clinically significant behavioral differences at age 4



# Reprogramming of Immune-Related Placental Gene Networks are Associated With At-Risk Anxiety in Early Childhood




Multiscale embedded gene co-expression network Analysis: functional co-expressed gene modules



Of the differentially correlated **cytokine-related genes**, the majority significantly correlate with **anxiety** exclusively in the **maternal cannabis group**

# Immune-Related Placental Gene Networks are Associated with At-Risk Anxiety in Early Childhood




Lipid processing: energy storage, signaling, and structural components of cell membranes






# THC/CBD Exposure To Pregnant Dams Alters the Placental Endocannabinoids




AEA, anandamide  
2-AG, 2-arachidonoylglycerol;  
DAGL, diacylglycerol lipase –  
produce 2-AG  
AA, Arachidonic acid

**Arachidonic acid — substrate** for both AEA and 2-AG synthesis and AA is recycled during endocannabinoid **catabolism**.

AA also acts as a shared substrate for the eicosanoid system, which produces prostaglandins.



## Prenatal THC Exposure Animal Model



Pregnancy

Infancy

Adolescence

Adulthood

Behavioral changes:  
Affective behavior

Behavioral changes:  
Affective behavior  
Social interaction

Behavioral changes:  
Motivation  
Depression-like phenotype  
Stress sensitivity  
Opioid sensitivity



# Prenatal Cannabinoid Effects on Juvenile Affect and Social Behaviors




Anissa Bara



Loredana Losapio

NF- $\kappa$ B gene expression (accumbens) and circulating cytokine levels  
Ultrasonic vocalization




Infancy (PND 10)

- Isolation-induced Ultrasonic Vocalizations
- Social communication
- Communicative role in mother-offspring interactions
- Peak at PND10 in rats




THC:CBD  
10:1

Social play








# Prenatal THC Exposure Alters Sensitivity to Opioids in Adulthood




■ vehicle  
■ THC



## Drug intake – mild stress



## Drug-seeking behavior




# Long-Term Consequences of Prenatal THC Exposure: Adulthood

Reward: chocolate




Forced Swim Test  
Behavioral despair model



Motivation


**Progressive ratio behavior**



Increased breakpoint = increased motivation


Depression-like phenotype

**Immobility behavior**



Hedonic state

**Sucrose intake**




# Underlying Mechanisms that Maintain *In Utero* Experiences Across Life?











ne methyltransferase  
al role in neurogenesis.  
riptional memory



# Epigenetic (Kmt2a) Perturbation *Causally* Contributes to Protracted Behavioral Effects in Adulthood due to Prenatal THC Exposure





# Gene Networks Associated with Kmt2a/H3K4me4 Epigenetic Alterations and Impacted by Prenatal THC in Adulthood Relate to Synaptic Plasticity





# Reorganization of Epigenetic Enrichment of Immune-Related Gene Loci in the Nucleus Accumbens of Adults with Prenatal THC Exposure



# ADOLESCENCE

~90% of adults with substance use disorders initiate use during adolescence

Migration

Synaptogenesis

**Adolescent cannabis use is a critical window for Cannabis Use Disorder risk**

## Youth and Young Adults:

- Among individuals who used cannabis, 22% met criteria for Cannabis Use Disorder (CUD).
- CUD was most prevalent in young adults, with the highest risk of CUD (41.1%) among the cohort of 21-year-old emerging adults.

Leung et al., *Addict Behav.* 2020

Childhood

Adolescence


Young adults

Fine tuning of neural circuits

Maturation of prefrontal cortex

Synaptic pruning

myelination



Past year cannabis use by teens:


- 8<sup>th</sup> graders: 11.4%
- 9<sup>th</sup> graders: 28%
- 12<sup>th</sup> graders: 35%

Giedd et al., *PNAS* 2004

Hurd, *J Clinical Invest*, 2020

# Association Between Cannabis Use Disorder and Schizophrenia: Sex and Age

For young men aged 21-30, the proportion of **preventable cases of schizophrenia related to cannabis use disorder** may be as high as 30%



PARF=Population attributable risk fraction. Modeled PARF= PARF results from the selected joinpoint regression model. APC=annual percentage change. AAPC=average APC during 1972-2021. APC=AAPC: Indicate that no joinpoints were identified using Bayesian Information Criterion.

**16–20-year-olds:** association between CUD and schizophrenia was **~2X as high for males than females**

**21–25-year-olds:** it was approximately **50% higher for males than females**

**>26 years old:** similar for males and females


Proportion of cases of schizophrenia associated with cannabis use disorder increased 3- to 4-fold during the past 2 decades



# The Prefrontal Cortex and Adolescent Cannabis Use


## Structurally

- Alters cortical thickness
- Alters grey matter/white matter ratio
- Alters gyrification



(Filbey et al. 2015; Shollenbarger et al. 2015)


Cannabis use associated with altered cortical development, particularly in prefrontal regions rich in CB1 receptors and exhibiting protracted maturational trajectories






**Accelerated cortical thinning correlated with cannabis use and impulsivity**

(Albaugh et al..IMAGEN., JAMA Psych, 2021)

# Adolescent THC Exposure: Prefrontal Cortex



## Reduced Cortical Neuronal Complexity



**RESEMBLES STRESS  
MORPHOLOGICAL  
PHENOTYPE in PFC**

Adol THC exposure



### Prelimbic (PrL) region of the Prefrontal Cortex:

- PFC subdivision during adolescence that exhibit the most pronounced developmental pruning and highest rate of spine turnover
- Layer II directly connected with amygdala, mediodorsal thalamus, nucleus accumbens








# Reprogramming of the Gene Expression Landscape in Pyramidal Cortical Neurons as a Consequence of Adolescent THC Exposure




THC



Overlap between genes differentially altered across adolescent development in THC animals and gene networks modules dysregulated in the prefrontal cortex of subjects diagnosed with schizophrenia

Kmt2a and H3K4me3 were the strongest functional association of the epigenetic gene network






## Endocannabinoid modulation

**High-potency cannabis** is associated with a greater risk of **psychotic symptoms, depression, anxiety, and cannabis use disorder.**

Adolescents only partially titrate their use of high-potency cannabis, which can result in the consumption of high concentrations of THC



## High Potency $\Delta^9$ -THC

high-THC (low-CBD) cannabis is preferred for recreational use

eCB


Exogenous cannabinoids

Normal  
synaptic  
regulation


Pathological  
synaptic  
regulation

# Adolescent THC Alters Stress System and Social Stress Impacts Reward Sensitivity: Dose Matters

## Stress hormone





## Acute isolation stress



## Amygdala molecular disturbances



**basolateral amygdala:** region critically implicated in decision making and anxiety/stress



**High dose THC alters cannabinoid receptor number in the amygdala that directly relates to impulsivity**

# Cannabis and Decision-Making Behavior

*Decision making is a critical cognitive facet implicated in psychopathologies, especially addiction*

Decision-making in Human Cannabis Users

---







# Re-Exposure to THC in Adulthood As a Consequence of Prior Exposure to THC During Adolescence

Adolescent THC exposure

Adult acute THC Challenge

Decision-Making Behavior







# Re-Exposure to THC in Adulthood After Adolescent THC Exposure

## Self-Administration


### Human cannabis use disorder



### Edible THC-Induced Decision-Making Deficits



### Stress-Induced THC Consumption








Amygdala

# Neurobiological Underpinnings



## High THC Dose — Stress Sensitivity and Astrocyte-Related Perturbation



High dose THC + Stress induce marked perturbation of astrocytes in the amygdala



THC-induced alterations of astrocytes within the amygdala directly relate to risky decision-making and impulsivity



Astrocytes – critical regulation of neuronal function

Stress resulted in ~400% increase in the number of DEGs vs. non-stressed conditions







Endocannabinoid System



Inhibit Stress Response



Frequent Cannabis  
use



Decreased levels of  
AEA and 2AG


Receptor Down  
regulation



Poor response to  
stress

With frequent use of  
cannabis, there is a  
loss of the normal  
inner 'brake'


### Cannabinoid Receptor Availability



D'Souza et al., *Biol. Psych*, 2017



The **plasticity** of the developing brain also offers windows of opportunity for prevention and early intervention to change that trajectory



# Developmental Cannabis Exposure

Potency matters

Early use matters

Frequency of use matters


Biological sex matters (but gap closing)

Behavioral traits/psychiatric comorbidity matters


Stress matters

Environment matters

Cannabinoid matters.....




$\Delta^9$ -THC



$\Delta^9$ -tetrahydrocannabinol



CBD




Cannabidiol

**Cannabis contains over 500 chemicals including >140 cannabinoids which have a greater or lesser degree of psycho-pharmaco-activity**









# Distinct Effects of THC and CBD On Heroin Vulnerability


**$\Delta^9$ -THC**




Enhance heroin self-administration



**CBD**




Decrease heroin seeking



# Cannabidiol as Potential Treatment Intervention for Opioid Relapse: Double-Blinded Placebo Control Study

Double-blind, Randomized, Placebo-Controlled: Participants with Opioid Use Disorder



Day 1

Day 2

Day 3

Day 10

Prescreen  
tests

Session 1

- CBD/PI
- Cue tests

Session 2

- Cue tests
- CBD/PI

Session 3

- CBD/PI
- Cognitive tests


Session 4

- Cue tests

CBD: 400 and 800 mg  
Placebo

# Cue-Induced Effects: Craving


## VAS-C






# Cue-Induced Effects: Anxiety

## VAS-A



# CBD Reduces Cue-induced Physiological Measures of Stress



# CBD Reduces Cue-Induced Drug-Seeking and Anxiety-like Behavior





Alex Chisholm




Jacqueline Ferland

CBD did not affect behavior in animals exposed to neutral cue or encoding of the cue behavioral response.



### Anxiety-like behavior




# CBD Normalizes or Reverses Neural Networks in the Accumbens Altered by Anxiety Phenotypes



Katie Lynch





Jacqueline Ferland



## Lipidomics

### Mitochondrial Respiration Transcripts



Gene modules that correlated with anxiety-like behavior involved mitochondria function



# CBD Normalizes or Reverses Neural Networks in the Accumbens Altered by Heroin-Seeking and Anxiety Phenotypes




Alex Chisholm



Jacqueline Ferland



Katie Lynch



Heroin seeking

Heroin




Anxiety


Anxiety





RNA-sequencing



Shared genes/biological processes



**Cannabis = Cannabinoid Exposure**





# NIDA

## Clinical Research Team



Alex Chisholm



Teesta Naskar



Konrad Drabowski


Diana Municchi



Jacqueline Ferland



Yoko Nomura



Jeremy Sherman



Kion Winston



Katie Lynch



Andre Toussaint



Chinara Tate




Jasper Van Oort



Gabrielle Zbaeren



Pavan Poojan



Joseph Landry



James Callens



Pamela Comlan



Daniel Garcia



Maria Purcell




Chris Kudrich



Burooj Mahmood



George Gardner



(Maria) Eli Savoia



Adam Dawoud



Sam Cartwright



Alfonso Brea Guerrero



Hanish Kodali



Ashanta Carter



Jenee Wilson



Olusegun (Shagun) Akinwolere